Literature DB >> 20462836

Evidence in medulloblastomas.

A Navajas1, J Giralt.   

Abstract

Medulloblastoma is the most common infratentorial malignant tumour under 15 years of age. In recent protocols, the patients are stratified for treatment in standard risk or high risk, according to the clinical variables as age, localized or disseminated disease, degree of surgical resection and more recently expected biological behaviour based on retrospective and prospective studies of former samples analyzed. The objectives for future treatments are reduce morbidity without jeopardizing survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462836     DOI: 10.1007/s12094-010-0503-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  44 in total

1.  Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.

Authors:  Thomas E Merchant; Larry E Kun; Matthew J Krasin; Dana Wallace; Murali M Chintagumpala; Shiao Y Woo; David M Ashley; Maree Sexton; Stewart J Kellie; Verity Ahern; Amar Gajjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-24       Impact factor: 7.038

2.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Authors:  Jacques Grill; Christian Sainte-Rose; Anne Jouvet; Jean-Claude Gentet; Odile Lejars; Didier Frappaz; François Doz; Xavier Rialland; Fabienne Pichon; Anne-Isabelle Bertozzi; Pascal Chastagner; Dominique Couanet; Jean-Louis Habrand; Marie-Anne Raquin; Marie-Cécile Le Deley; Chantal Kalifa
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

3.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

4.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

5.  Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.

Authors:  Katja von Hoff; Wolfgang Hartmann; André Oscar von Bueren; Nicolas Ulrich Gerber; Michael Andreas Grotzer; Torsten Pietsch; Stefan Rutkowski
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

6.  Medulloblastoma in children under the age of three years: a retrospective Canadian review.

Authors:  Donna L Johnston; Daniel Keene; Ute Bartels; Anne-Sophie Carret; Bruce Crooks; David D Eisenstat; Chris Fryer; Lucie Lafay-Cousin; Valerie Larouche; Albert Moghrabi; Beverly Wilson; Shayna Zelcer; Mariana Silva; Josee Brossard; Eric Bouffet
Journal:  J Neurooncol       Date:  2009-01-31       Impact factor: 4.130

Review 7.  The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.

Authors:  Barry L Pizer; Steven C Clifford
Journal:  Br J Neurosurg       Date:  2009-08       Impact factor: 1.596

8.  Medulloblastoma: time-dose relationship based on a 30-year review.

Authors:  J O del Charco; T W Bolek; W M McCollough; B L Maria; A Kedar; R C Braylan; J P Mickle; J M Buatti; N P Mendenhall; R B Marcus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

9.  Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma.

Authors:  W H St Clair; J A Adams; M Bues; B C Fullerton; Sean La Shell; H M Kooy; J S Loeffler; N J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Authors:  Dawn Elizabeth McNeil; Timothy R Coté; Limin Clegg; Lucy Balian Rorke
Journal:  Med Pediatr Oncol       Date:  2002-09
View more
  4 in total

1.  Outcome and toxicity using helical tomotherapy for craniospinal irradiation in pediatric medulloblastoma.

Authors:  J L Lopez Guerra; I Marrone; J Jaen; M Bruna; C Sole; A Sanchez-Reyes; E Rivin; M J Ortiz; F Calvo; R Matute
Journal:  Clin Transl Oncol       Date:  2013-04-30       Impact factor: 3.405

2.  Toxicity Reduction after Craniospinal Irradiation via Helical Tomotherapy in Patients with Medulloblastoma: A Unicentric Retrospective Analysis.

Authors:  Anil Öztunali; Khaled Elsayad; Sergiu Scobioala; Mohammed Channaoui; Uwe Haverkamp; Oliver Grauer; Ronald Sträter; Angela Brentrup; Walter Stummer; Kornelius Kerl; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

3.  Pulmonary toxicity of craniospinal irradiation using helical tomotherapy.

Authors:  Joongyo Lee; Euidam Kim; Nalee Kim; Chang-Ok Suh; Yoonsun Chung; Hong In Yoon
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.379

4.  Malignant behaviorial characteristics of CD133(+/-) glioblastoma cells from a Northern Chinese population.

Authors:  Xiaozhi Liu; Lei Chen; Zhongmin Jiang; Junfei Wang; Zhiguo Su; Gang Li; Shizhu Yu; Zhenlin Liu
Journal:  Exp Ther Med       Date:  2012-10-15       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.